Tolerability and treatment response to darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) in the phase 3 ARAMIS trial

    Activity: Talk or presentation › Conference presentation

    Description

    Contributors: Fizazi Karim Shore Neal Smith Matthew Tammela Teuvo Le Berre Marie-Aude Petrenciuc Oana Zurth Christian Kuss Iris
    Period17 Sept 2020
    Event titleESMO Virtual Congress 2020
    Event typeOther
    Degree of RecognitionInternational

    Documents & Links